| GPCRS TARGETED FOR OBESITY |
Development of an Inverse Agonist for CB1.
Tung M. Fong, Ph.D., Director, Obesity & Metabolic Disorders, Merck Research Laboratories
Agonists of GPR119/GDIR Mediate Glycemic Control via Glucose Dependent Insulin and Incretin Release
Rob Jones, Ph.D., Director, Medicinal Chemistry, Arena Pharmaceuticals
Discovery of MCH R1 Antogonist for the Treatment of Obesity: Taming hERG.
Jing Su, Ph.D, Principal Scientist, Chemical Research, Schering-Plough Research Institute |
| DEORPHANIZATION |
Featured Speaker
Deorphanization of GPCRs
Olivier Civelli, Ph.D., Professor and Chair, Neuropharmacology, University of California Irvine |
|
| NEUROPYSCHIATRIC DISORDERS |
Science and Serendipity: Discovery of Novel Adenosine A2A Antagonists for the Treatment of Parkinson’s Disease
Allan Jordan, Ph.D., Team Leader, Medicinal Chemistry, Vernalis
Dual NK3/NK1 Receptor Antagonism: A Novel Approach for the Treatment of Psychotic Disorders
Patrick Schnider, Ph.D., Project Leader, PRBD-CM, F. Hoffman-La Roche Ltd.
|
TECHNOLOGY SPOTLIGHT
New GPCR Modeling Toolkit with a Focus on Structural Refinement of Homology Models
Woody Sherman, Ph.D., Applications Scientist, Schrödinger, LLC |
